Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients

Mounika Vasa; Madhukar Rao Polasani; Ravi D Mala; Anurag Yadav; Patil Banderao Venkatrao

doi:10.5455/njppp.2023.13.03115202218052022

2023, Vol: 13, Issue: 5

13/5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2023; 13(1): 21-26

doi: 10.5455/njppp.2023.13.03115202218052022

Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients

Mounika Vasa, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, Patil Banderao Venkatrao.

Abstract
Background: The common cause of mortality in India is related to complications of cardiovascular disease which has direct relation with the hyperlipidemia, diabetes mellitus, and hypertension. Rosuvastatin more efficacious than other statins in lesser dosage and having good safety profile.

Aim and Objective: The present study was undertaken to evaluate the safety, efficacy of rosuvastatin 10 mg daily dose versus alternate day dose in hyperlipidemia patients.

Materials and Methods: A total of 50 individuals with hyperlipidemia were selected in this prospective open label research. Patients were grouped as Group D with rosuvastatin daily dose and Group A with alternate day dose. Fasting plasma lipid profile was assessed in both groups on the 1st, 4th, and 6th weeks.

Results: There is significant reduction in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and elevation of high-density lipoprotein (HDL) after 4 weeks and 6 weeks of the treatment in both the groups compared to baseline. The mean percentage reduction of total cholesterol was by 24% and 21.60% (P < 0.05) in Group D and Group A, respectively. The mean percentage reduction of LDL-C was by 33.50% and 31% (P < 0.05) Group D and Group A, respectively. The mean percentage improvement of HDL-cholesterol was by 19.89% and 17.09% (P < 0.05) in Group D and Group A, respectively. The mean percentage of reduction of TG was by 36.70% and 41.33% (P < 0.05) Group D and Group A.

Conclusion: Rosuvastatin 10 mg on alternate days had the same efficacy in lowering cholesterol levels as taking it every day, also it may be a cost-effective alternative without sacrificing therapeutic benefits or side effects.

Key words: Rosuvastatin; Cholesterol; Cost-effective; Safety; Hyperlipidemia

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Mounika Vasa Articles by Madhukar Rao Polasani Articles by Ravi D Mala Articles by Anurag Yadav Articles by Patil Banderao Venkatrao
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Web Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. https://www.njppp.com/?mno=100051 [Access: May 01, 2023]. doi:10.5455/njppp.2023.13.03115202218052022

AMA (American Medical Association) Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Vancouver/ICMJE Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. (2023), [cited May 01, 2023]; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Harvard Style

Vasa, M., Polasani, . M. R., Mala, . R. D., Yadav, . A. & Venkatrao, . P. B. (2023) Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Turabian Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. 2023. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Chicago Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. "Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 21-26. doi:10.5455/njppp.2023.13.03115202218052022

MLA (The Modern Language Association) Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. "Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13.1 (2023), 21-26. Print. doi:10.5455/njppp.2023.13.03115202218052022

APA (American Psychological Association) Style

Vasa, M., Polasani, . M. R., Mala, . R. D., Yadav, . A. & Venkatrao, . P. B. (2023) Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article